Skip to main content
< Back to news
 20.11.2024

Stefanos Theoharis, CEO of OneChain Immunotherapeutics: “We bring scientific advances from the laboratory to patients to transform the lives of people affected by cancer.”

OneChain Immunotherapeutics (OCI), based at the Parc Científic de Barcelona, is a biotechnology company dedicated to the development of advanced cancer therapies. Its innovative technology is based on the genetic manipulation of immune cells, T cells in particular, which are modified to identify and eliminate cancer cells with precision. These cells can come from the patient themselves, from a donor or from stem cells, which are differentiated and multiplied in the laboratory before being used therapeutically.

The company’s CEO, Stefanos Theoharis, explained that the company got its start tackling T-cell leukaemia, a disease still in need of extensive medical research and directly linked to the legacy of Josep Carreras and his Leukaemia Research Institute. In fact, this institute was where the initial discoveries leading to the company’s creation were made. Currently, OCI is working to expand the impact of this technology to solid tumours, in the hope of reaching more patients and transforming cancer treatment.